PDS Biotechnology Corp 8-K
Research Summary
AI-generated summary
PDS Biotechnology Corp Regains Nasdaq Minimum Bid Compliance
What Happened
PDS Biotechnology Corporation (PDSB) announced in an 8-K (Item 8.01) that Nasdaq notified the company on June 2, 2026 that it has regained compliance with the $1.00 minimum closing bid price required for continued listing on The Nasdaq Capital Market. The company had previously received a Nasdaq deficiency letter on February 25, 2026 regarding noncompliance with Nasdaq Listing Rule 5550(a)(2).
Key Details
- Nasdaq deficiency letter received February 25, 2026 citing a sub-$1.00 closing bid for the last 30 consecutive business days.
- Nasdaq notified PDSB on June 2, 2026 that the company has regained compliance with the Minimum Bid Price Requirement.
- Nasdaq has closed the matter following the company's return to compliance.
Why It Matters
Regaining compliance means PDSB remains listed on The Nasdaq Capital Market, preserving its current public listing status and the associated market access and liquidity for shareholders. The Nasdaq closure of the matter removes the immediate regulatory risk that was disclosed in the earlier deficiency notice.
Loading document...